PRESS RELEASE
2 June 2022
Trichome Pharma Announces Approval of Cannabis Cultivation License for R&D Purposes and Website Launch
Madrid – Trichome Pharma, a Spanish pharmaceutical company specialized in medicinal-grade cannabis and hemp-derived consumer healthcare, announces that it has received approval from the Spanish Agency of Medicines and Medical Devices (AEMPS) to cultivate medicinal cannabis for research purposes. The company is also thrilled to announce the launch of its new website, inviting visitors to explore and learn more about the business.
Trichome Pharma was founded in 2020 with the ambitious goal of helping to shape a future where cannabis is considered a viable alternative in mainstream healthcare for patients and consumers. Over the past 18 months, the company has been operating in stealth mode while building its research and development platform, with the aim of broadening access to medicinal cannabis and setting a new benchmark in quality and innovation for medicinal-grade starter materials and finished products.
With their research license secured, Trichome Pharma can advance a full pipeline of projects to the next phase, including the development of novel micropropagation and conservation techniques for large-scale plant production, the study and selection of various cannabis cultivars from their bank of genetics, and the development of innovative cultivation strategies and protocols to optimize plant quality, performance and potency.
“Receiving AEMPS approval is a significant milestone for the company that marks the culmination of many months of hard work. It’s a really exciting time to be in this industry. I’ve always believed that Spain is the perfect place to build and grow a cannabis business. Not only does it possess a world class agricultural sector and optimal climatic conditions for cannabis cultivation, but it also has a rich ecosystem of knowledgeable industry experts and a deeply-rooted culture in cannabis. Of course, we’d love to see domestic regulation evolve in the same way other European markets have and trust this will happen in the not too distant future.” Says Nicholas Balk, CEO of Trichome Pharma and Managing Director of Trichome Capital.
The market for regulated cannabis in Europe continues to grow in leaps and bounds, while positive momentum is building on the supply side in Spain, with the list of entities (both public and private) holding cultivation licenses from AEMPS growing to 21. Trichome Pharma believes it will set itself apart through its focus on sustainable cultivation and innovation coming from its R&D platform. The company has a lot more of exciting projects and news to share, which it looks forward to announcing in the weeks to come.
About Trichome Pharma
Trichome Pharma is a leading pharmaceutical company specialized in the cultivation, development, and commercialization of medicinal-grade cannabis and hemp-derived consumer healthcare products. Its activities include agronomic research, product innovation, brand development, market access and distribution, as well as education and social awareness.
Trichome Pharma’s operations, consisting of organically-certified outdoor cultivation and low-touch greenhouse facilities, provide the perfect conditions for growing the best and highest quality cannabis available. Downstream, it’s developing Spain’s first family of wellness brands based on phytocannabinoids, targeting high-growth consumer healthcare niches with attractive margins.
Members of
About Trichome Capital
Trichome Capital is an independent advisory firm specialized in providing corporate finance, strategic consulting and investment management services to the regulated cannabis industry and parallel sectors including the agri-food value chain and healthcare. In 2020, with the support of trusted investors, the firm launched its first cannabis investment vehicle focused on developing and investing in leading, legal, “cannabusinesses” in Spain and abroad.
Find out more at: https://trichomecp.com/
